To quantify the downstream impact of PSA testing on cancer characteristics and utilization of cancer therapies among men aged 70 or older, we utilized patients diagnosed with prostate cancer in [2004][2005] Men in the high testing group were 3.57 times more likely to receive cancer treatments (either surgery, radiation or hormonal therapy) when compared with men who had no previous PSA testing during the same time period. Among men aged 75 þ diagnosed with low-risk cancer, men in the high testing group were 78% more likely to receive treatment than those who had no previous PSA testing. In conclusion, given the lack of evidence of effective treatment for elderly patients diagnosed with low-and intermediate-risk prostate cancer and our inability to distinguish indolent from aggressive cancer, more frequent PSA testing among elderly population may exacerbate the risk of overdiagnosis and overtreatment.
Introduction
Screening for prostate cancer by PSA gained widespread acceptance in the United States following a 1987 report by Stamey et al. 1 More intensive PSA screening for prostate cancer has resulted in a higher prostate cancer incidence. 2 Unfortunately, no therapies have been shown to extend cause-specific survival for men over aged 65 diagnosed with low-or intermediate-risk prostate cancer. [3] [4] [5] Currently, the 5-year relative survival rate for patients diagnosed with localized disease is almost 100% regardless of whether patients receive therapy or not. 6 Although PSA testing can detect prostate cancer at an earlier stage and potentially improve survival, it is also associated with a significant risk of overdiagnosis and overtreatment. 7 The U.S. Preventive Services Task Force (USPSTF) recommends against PSA screening for men over age 75 due to the concern that the risk of overdiagnosis and overtreatment may outweigh the benefits of testing. 8 Despite evidence suggesting that PSA testing might be safely discontinued for most men older than 75, 9 the screening rate remains high in this group. 10, 11 Since 2000, Medicare has paid for annual PSA testing without an upper age limit, eligibility requirements or evaluation. To quantify the downstream impact of PSA testing on utilization of treatments, we performed a nation-wide population-based study among Medicare recipients in the United States.
Materials and methods

Data sources
We conducted a population-based retrospective cohort study utilizing data obtained from files linking information from the Surveillance, Epidemiology and End Results (SEER) program with Medicare claim files. The SEER regions encompass B25% of the United States population, whereas the Medicare claim files cover B93% of patients aged 65 years and older. 12 
Study participants
Our study included 24 
Measurement of PSA testing and treatment intensity
We used claims for PSA testing from Current Procedure Terminology codes 84153 or G0103 reported in the physician/supplier and outpatient files within Medicare as measurement of PSA testing intensity. 10, 13 We calculated the number of claims for PSA testing from 2000 to 2005, excluding PSA testing that occurred after diagnosis of prostate cancer. More than 90% of men had only one claim for PSA testing each year. We counted the multiple PSA tests men received in 1-year period as one single PSA test because we wanted to estimate the proportion of men receiving at least one PSA testing before cancer diagnosis. The study population was divided into five groups (never, one, two, three, or four to six tests) based on the number of annual PSA tests received from 2000 to 2005.
Treatment administered following diagnosis was categorized as either active treatment or conservative management. Active therapy consisted of men receiving radical prostatectomy, radiation therapy (that is, external beam radiation therapy and/or brachytherapy) or primary androgen deprivation therapy within 180 days following diagnosis. Conservative management included men not receiving radical prostatectomy, radiation or primary androgen deprivation therapy as recorded in the SEER-Medicare data set.
Data elements and study groupings
Patient characteristics and cancer status were measured at the time of cancer diagnosis. The health status of the study population was assessed using the Charlson comorbidity index, 14 a summary measure based on 19 chronic diseases selected and weighted according to their association with mortality. To study the association between health status and the chance to receive PSA testing, each study participant was assigned a Charlson score based on information available from Medicare physician, inpatient and outpatient claims during the 12 month period before the start of 2000. 15 Based on this information, the study population was divided into three categories: good health (Charlson score 0), average health (Charlson score 1) and poor health (Charlson score X2). Other variables known to influence PSA testing including education level, income, race, geographic location, number of physician visits and marital status were obtained from SEER-Medicare linkages to the 2000 U.S. census data.
To assess cancer status at diagnosis, men were categorized into three risk groups using the American Joint Committee on Cancer classification system, 16 
Data analyses
The association between Gleason score, cancer stage, risk categories at diagnosis and the number of annual PSA tests received were evaluated by the Mantel-Haenszel statistic. 18 The association between age and PSA level at diagnosis and the number of annual PSA tests received was examined by one-way analysis of variance using linear contrast. The distribution of the number of annual PSA tests received before diagnosis stratified by age, race, health conditions and other characteristics present at diagnosis was evaluated by the asymptotic KruskalWallis test. 19 We used ordinal logistic regression models to estimate multivariate-adjusted odds ratios and 95% confidence intervals to determine the association between each patient characteristic and the number of annual PSA tests received before diagnosis. In addition, we used multivariable logistic regression to estimate the association between each variable, the number of PSA tests received and the receipt of treatments. The distribution of treatments stratified by the number of PSA tests and risk groups was evaluated using the Cochran--MantelHaenszel statistic.
All statistical tests were two-sided and were performed by using SAS version 9.1.3 (SAS Institute, Cary, NC, USA).
Role of the funding source
This study was funded by National Cancer Institute, Cancer Institute of New Jersey and Robert Wood Johnson Foundation. The funding sources had no role in the design of our analysis, its interpretation or the decision to submit the manuscript for publication.
Results
Characteristics of the patients and their pre-diagnosis PSA testing use are described in Table 1 Men who are white, with higher education, more affluent, married and had more physician visits 1 year before cancer diagnosis are more likely to receive a higher number of PSA tests before cancer diagnosis. Increasing numbers of PSA tests before cancer diagnosis were associated with decreasing PSA levels at diagnosis, lower biopsy Gleason scores, lower clinical stages and lower risk disease (Po0.001) ( Table 2 ). The median PSA at diagnosis decreased from 11.9 ng ml À1 for patients who had never been previously tested to 7.2 ng ml À1 for patients who received four to six annual tests (Po0.001). Among men in the highest testing group (4-6 PSA tests), 75% were diagnosed with low-or intermediate-risk of disease but 77% received treatments in 180 days.
Factors predicting the frequency of annual PSA testing before diagnosis are listed in Table 3 . In our initial model PSA screening and cancer treatment in old men Y-H Shao et al (results not shown), age was the strongest predictor of annual testing, but surprisingly, increased Charlson score was associated with an increased frequency of annual PSA testing after adjusting for other factors. We anticipated that number of physician visits might relate to the number of PSA tests received and included this variable in our final model. In this final model, the number of physician visits in 1 year before cancer diagnosis was strongly associated with the chance of receiving a PSA test (Table 3) . Men in poor health status was no longer related to a higher chance of receiving PSA tests after adjusting for number of physician visits when compared with men in good health status. Patients who were white, married, or had relatively higher incomes and education had a higher chance to have annual PSA tests.
Factors predicting a higher frequency of PSA testing also predicted the likelihood of receiving cancer therapy (Table 3) . Compared with men who had never been tested, the chance of receiving a cancer treatment was 2.83 (95% confidence interval: 2.48-3.24) times in men who received only one PSA test and 3.57(95% confidence interval: 3.14-4.05) times in men who received 4-6 PSA tests. This was true for men in all age categories and health conditions. Men who lived in the northeast area were more likely to receive treatments than men who lived in other regions. Figure 1 presents the treatment pattern among men aged 75 and older who were diagnosed with prostate cancer stratified by the number of previous annual PSA tests and cancer risk groups. Men who received more than one PSA testing before diagnosis were more likely to receive treatments within 180 days (Po0.005). In the low-risk group, men who underwent four to six PSA tests were 1.78 times more likely to received treatments compared with men who had not had annual PSA tests (Po0.005). Radical prostatectomy and radiation therapy were more common among lowand intermediate-risk patients than among high-risk patients. PSA screening and cancer treatment in old men Y-H Shao et al
Discussion
Our findings suggest that men receiving more PSA tests before cancer diagnosis is associated with a higher chance in receiving cancer therapy. Among men in the highest testing group (4-6 PSA tests), 75% were diagnosed with low-or intermediate-risk of cancer but 77% received treatments in 180 days. Only 50% of men who had no previous PSA test received active therapy. Our previous study 7 showed that aggressive local therapy was provided to most patients diagnosed with prostate cancer due to the inability to distinguish indolent from aggressive cancers. Results from this study further demonstrated that more intensive PSA testing among the elder population is likely to exacerbate the risk of overdiagnosis and overtreatment.
Screening in the United States is predominantly opportunistic. Opportunistic screening depends on the health care providers to recommend screening or on individuals to request screening. It involves fewer formal decisions regarding whom to screen, whether to screen and at what interval. Among men diagnosed with prostate cancer in 2004-2005, almost half have undergone annual PSA testing before their diagnosis and many of these men have a limited life expectancy. Our results demonstrate that PSA testing appears to correlate more with the number of physician visits rather than the risk of developing prostate cancer or the health status of the patient. The possibility that opportunistic screening could cause more harm than good has been a concern. 20 Although intensive PSA testing may diagnose patients at an earlier stage of cancer, data from ERSPC study demonstrated that cancers diagnosed from repeated screening has a minimal effect on detecting clinically significant disease, 21, 22 and are not associated with reduced prostate cancer mortality. 2 Despite this evidence many clinicians continue to screen Medicare eligible men annually, possibly because they overestimate the benefit and do not appreciate the potential harms of PSA screening. Many may lack the time to explain the pros and cons of PSA screening strategies whereas others may be concerned about medical-legal implications. 23, 24 Our results support the USPSTF concern of screening men with less than a 10-year life expectancy because of the increased likelihood of harm from the consequence of screening relative to any potential benefit. 25 For men aged 75 and older with low-risk prostate cancer, active surveillance may be the best treatment option when compared with the treatment-related side effects and the modest survival benefit associated with more aggressive treatment. [3] [4] [5] 26 However, we found that men with lowrisk cancer were treated intensively after cancer diagnosis. Men who had 4-6 PSA tests before diagnosis were much more likely to receive treatment within 180 days, particularly radiation therapy, than men who did not have PSA test. Men who had assumed they would benefit from early detection and cancer treatment before receiving a PSA test and the number of PSA tests they received before cancer diagnosis could be interpreted as their level of belief regarding PSA screening for prostate cancer.
Medicare started to cover annual PSA tests since 2000 despite the uncertainty surrounding the cost-effectiveness to provide PSA testing for early detection. 27 In 2004, 110 (8) 266 (7) 165 (5) 141 (4) 252 (3) Unknown 137 (9) 277 (8) 151 (4) 128 (4) 286 (3) Risk group, % Low 279 (19) 617 (17) 801 (24) 1109 (29) 
PSA screening and cancer treatment in old men Y-H Shao et al
Medicare expenditures for prostate cancer ranked third highest among cancer patients after lung cancer and colorectal cancer. 28 Along with evidence suggesting the lack of benefit to screen men who are aged 75 and above, 5 our data show that more frequent PSA testing and the subsequent diagnosis of additional prostate cancers often lead to more cancer therapies that may not result in reduced prostate cancer mortality. Therefore, specifying screening eligibility criteria and screening interval may yield benefits at the population level. 29, 30 If Medicare beneficiaries follow the USPSTF recommendation of no screening after age of 75 or screened only once in a 4-year interval, many men would be spared a cancer diagnosis and treatment. Consequently, Medicare costs would decrease dramatically with a modest impact on prostate cancer mortality.
Strengths and limitations
This is the first population-based study documenting the association between PSA testing frequency and prostate cancer treatment patterns among Medicare beneficiaries. The linked data set provided the power to study the consequence of PSA testing because of its size but limited our analysis to men diagnosed with prostate cancer at age 70 years and older. We cannot distinguish PSA screening from diagnostic PSA testing in Medicare claims where men might receive PSA test because of Only radical prostatectomy, radiation therapy or hormone therapy received within 180 days after diagnosis were included. Radical prostatectomy includes patients who received radical prostatectomy alone or with radiation therapy or hormone within 180 days after diagnosis. Radiation therapy includes patients who received radiation therapy alone or with hormone. Difference across number of PSA tests was statistically significant for all risk groups.
PSA screening and cancer treatment in old men Y-H Shao et al
The USPSTF recommendation against screening for men aged 75 and older is because of concerns that the risks may outweigh benefits among men with limited life expectancy. Our study supports the concerns by showing the substantial downstream effect on treatment utilization. Because prostate cancer progresses slowly and the 10 year disease specific mortality is low, 31 we could not evaluate the association between PSA testing and prostate cancer specific mortality. Previous studies suggest that more intensive screening and treatment is not associated with lower prostate cancer mortality among elderly men. 2 
Conclusion
Our study reveals the profound impact of intensive PSA testing on cancer diagnosis and treatment. Given the lack of evidence of effective treatment for men older than 65 years of age diagnosed with low-and intermediate-risk prostate cancer and our inability to distinguish indolent from aggressive cancer, intensive PSA testing is likely to exacerbate the risk of overdiagnosis and overtreatment among elderly men.
